日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Brexucabtagene autoleucel 用于 BTKi 初治复发/难治性套细胞淋巴瘤：ZUMA-2 队列 3 的主要分析

期刊:Blood
影响因子:23.1
doi:10.1182/blood.2025029734
van Meerten, Tom; Kersten, Marie José; Iacoboni, Gloria; Hess, Georg; Mutsaers, Pim; García-Sancho, Alejandro Martín; Goy, Andre; Giné, Eva; Hill, Brian T; Weng, Wen-Kai; Reagan, Patrick M; Patel, Krish; Galal, Ahmed; Herbaux, Charles; Sanderson, Robin; Forcade, Edouard; Topp, Max S; Houot, Roch; Zheng, Dan; Zhang, Wangshu; Kanska, Justyna; Shen, Rhine R; Damico Khalid, Rita; Kloos, Ioana; Dreyling, Martin; Wang, Michael L
BTK
细胞生物学
淋巴瘤
发表日期：2026
文献求助 收藏

Corrigendum to "Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL" [Mater. Today Bio (35) 102267]

对“肿瘤归巢外泌体能够靶向递送siRNA和异异戊二烯素以克服DLBCL中的BTK抑制剂耐药性”的更正[Mater. Today Bio (35) 102267]

期刊:Materials Today Bio
影响因子:10.2
doi:10.1016/j.mtbio.2026.103005
Sun, Ruowen; Yang, Yanchao; Zhang, Bin; Chen, Jiayuan; Wang, Ye; Jiang, Zehui; Zhang, Linlin; Ashrafizadeh, Milad; Sethi, Gautam; Shen, Jing; Chi, Zuofei
BTK
外泌体
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study

伊布替尼或非BTK抑制剂治疗复发性华氏巨球蛋白血症：一项意大利多中心真实世界研究

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017464
Autore, Francesco; Tedeschi, Alessandra; Benevolo, Giulia; Danesin, Nicolò; Giannarelli, Diana; Rizzi, Rita; Cencini, Emanuele; Mattiello, Veronica; Ferrarini, Isacco; Pasquale, Raffaella; Del Giudice, Ilaria; Ferrari, Angela; Bullo, Martina; Rossini, Bernardo; Motta, Marina; Marino, Dario; Innocenti, Idanna; Stirparo, Luca; Petrilli, Diego; Musto, Pellegrino; Peri, Veronica; Zamprogna, Giulia; Hohaus, Stefan; Frustaci, Anna Maria; Piazza, Francesco; Ferrero, Simone; Laurenti, Luca
BTK
发表日期：2026
文献求助 收藏

TP53-aberrated CLL: is BTK inhibitor monotherapy enough?

TP53异常型慢性淋巴细胞白血病：BTK抑制剂单药治疗是否足够？

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017954
Niemann, Carsten Utoft
P53
BTK
细胞生物学
白血病
发表日期：2026
文献求助 收藏

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study

Pirtobrutinib，一种高选择性、非共价（可逆）BTKi，用于治疗复发/难治性边缘区淋巴瘤：BRUIN 1/2期研究

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017489
Patel, Krish; Vose, Julie M; Nasta, Sunita D; Brown, Jennifer R; Maddocks, Kami J; Woyach, Jennifer A; Shah, Nirav N; Fakhri, Bita; Tessoulin, Benoit; Ma, Shuo; Jagadeesh, Deepa; Lech-Maranda, Ewa; Coombs, Catherine C; Patel, Manish R; Rhodes, Joanna M; Ujjani, Chaitra; Hoffmann, Marc S; Cheah, Chan Y; Munir, Talha; Lewis, David; Scarfò, Lydia; Eyre, Toby A; Alencar, Alvaro; Cohen, Jonathon B; Zelenetz, Andrew D; Tsai, Donald E; Li, Mei; Bian, Yuanyuan; Abada, Paolo; Balbas, Minna; Zinzani, Pier Luigi
BTK
淋巴瘤
发表日期：2026
文献求助 收藏

Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

更正：复发/难治性弥漫性大B细胞淋巴瘤患者在接受抗CD19 CAR-T细胞治疗前，不同疗程BTK抑制剂桥接治疗的预测因素和疗效

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2026.1814535
Wang, Jia; Cui, Rui; Qi, Yao; Mu, Juan; Li, Xin; Li, Qing; Deng, Qi
B细胞
T细胞
淋巴瘤
T细胞
BTK
细胞生物学
CD19
免疫/内分泌
发表日期：2026
文献求助 收藏

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

复发/难治性弥漫性大B细胞淋巴瘤患者在接受抗CD19 CAR-T细胞治疗前，采用不同持续时间的BTK抑制剂桥接治疗的预测因素和疗效

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2026.1674235
Wang, Jia; Cui, Rui; Qi, Yao; Mu, Juan; Li, Xin; Li, Qing; Deng, Qi
B细胞
T细胞
淋巴瘤
T细胞
BTK
细胞生物学
CD19
免疫/内分泌
发表日期：2026
文献求助 收藏

First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of BIIB091, an Oral BTK Inhibitor, in Healthy Adult Participants

在健康成年受试者中首次进行口服 BTK 抑制剂 BIIB091 单次和多次递增口服剂量的人体安全性、耐受性、药代动力学和药效学研究

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S571780
Tsai, Hui-Hsin; Gu, Yi; Riester, Katherine; Chu, Sherman S; Bame, Eris; Arefayene, Million; Kam, Jeanelle L Y L; Coppell, Alexander; Hanna, Jerome; Hopkins, Brian T; Scaramozza, Matthew
BTK
Human
发表日期：2026
文献求助 收藏

BTK-Inhibitor Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Targeting Elimination of Autoreactive BAFFR(high) B Cells

载有BTK抑制剂的聚合物纳米颗粒通过靶向清除自身反应性BAFFR(high) B细胞来缓解系统性红斑狼疮

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms27020729
Zhang, Yamin; Wen, Jingjing; Jiang, Biling; Jiang, Hao; Xu, Jian; Tao, Juan
B细胞
BAF
红斑狼疮
BTK
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis

布鲁金沙（Zanubrutinib）是复发或难治性慢性淋巴细胞白血病中更安全的布鲁顿酪氨酸激酶（BTK）抑制剂吗？一项系统评价和荟萃分析

期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph19030467
Hetta, Helal F; Salama, Ayman; Aljuaid, Turki A; Mojmami, Yazan T; Alotibi, Riyadh S; Alqabaly, Ahmed M; Aldosari, Nawaf A; Alshahri, Sami A; Asiri, Walid I A; Alamri, Raed S; Alanazi, Fayez A; Alenazi, Malek S A; Albuhayri, Mohammed H; Ramadan, Yasmin N; Sayad, Reem
信号转导
BTK
细胞生物学
白血病
发表日期：2026
文献求助 收藏